Quantcast

Latest UCB Stories

2014-09-15 16:28:40

Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from several exploratory analyses of the Phase 2 study evaluating romosozumab in postmenopausal women with low bone mineral density (BMD). Romosozumab is an investigational bone-forming agent that is designed to work by inhibiting the protein sclerostin, thereby...

2014-09-01 00:21:00

- VIMPAT® (lacosamide) C-V approved in the U.S. as monotherapy in the treatment of partial-onset seizures in adults with epilepsy(1) BRUSSELS, Sept. 1, 2014 /PRNewswire/ -- 0700 (CEST) - regulated information -- UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VIMPAT(®) (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.(1) This is a new...

2014-08-22 16:23:24

DUBLIN, Aug. 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr. Actavis' ANDA product is a generic version of UCB's Neupro(®), which is indicated for the treatment of signs and symptoms of idiopathic Parkinson's...

2014-07-03 08:23:24

- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical leader (Euronext: UCB), and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia(®) (certolizumab pegol) in dermatology. This collaboration aims...

2014-04-30 08:32:32

ATLANTA, April 30, 2014 /PRNewswire/ -- Today, the U.S. Department of Veterans Affairs' Epilepsy Centers of Excellence (ECoE), biopharmaceutical company UCB, and health data sharing network PatientsLikeMe(®) presented the results of the Policy for Optimal Epilepsy Management (POEM) study at the 66(th) Annual Meeting of the American Academy of Neurology in Philadelphia, Pa. This first-time, real-world study of an online health management platform demonstrated statistically significant...

2014-01-08 12:30:46

ATLANTA, Jan. 8, 2014 /PRNewswire/ -- The Celtaxsys Board of Directors today announced that Greg Duncan has been appointed as President and Chief Executive Officer (CEO) and will join the board of directors effective immediately. Mr. Duncan joins Celtaxsys following his most recent role as an Executive Committee member and President of North America for Brussels based UCB, prior to which he served as a Senior Vice-President at Pfizer where his duties included leading US marketing, as...

2014-01-01 16:20:13

THOUSAND OAKS, Calif. and BRUSSELS, Jan. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck....


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related